Khosla Impact

Overture Life, Inc. is a biotechnology company based in New York, established in 2017, that specializes in developing robotic solutions for in vitro fertilization (IVF) applications. The company focuses on automating the IVF process through innovative medical devices and embryo testing methodologies, which enhance the efficiency and success rates of fertility treatments. By optimizing resource use and lowering costs, Overture Life aims to make IVF more accessible to a broader audience. Its technology includes automated cryopreservation and embryo testing services, enabling fertility clinics to identify viable embryos prior to implantation, thereby improving patient outcomes and supporting individuals in their journey to parenthood.

Science is a startup company that develops technologies for a range of serious unmet medical needs.

Tempero Bio is a clinical-stage biopharmaceutical company focused on developing transformative therapies for treating and preventing substance use disorders. The company aims to address the challenges faced by individuals struggling with addiction, providing innovative treatments that facilitate recovery and improve overall health outcomes. By specializing in this critical area of healthcare, Tempero Bio seeks to make a meaningful impact on the lives of patients affected by substance use disorders and related conditions.

ReSource Chemical is a company based in Berkeley, California, focused on developing high-performance plastics derived from carbon dioxide. The company utilizes a proprietary bio-based platform to create chemicals that enable the production of environmentally friendly plastics with superior physical properties compared to traditional fossil fuel-based plastics. By converting CO2 into these innovative materials, ReSource Chemical aims to provide sustainable alternatives that do not contribute to environmental pollution.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive food analytics platform that utilizes next-generation sequencing and data analytics to enhance food safety and quality control. Its offerings include Clear Dx™ and Clear Safety™, which facilitate the rapid identification of pathogens and support public health initiatives. Clear Labs' platform delivers critical insights into the molecular composition of foods and ingredients, testing for authenticity, contaminants, allergens, and other safety parameters. By offering transparency across supply chains, the company serves food manufacturers, suppliers, and retailers, enabling them to improve operational efficiency and safety through detailed analytics and reporting.

Enzymit is a biotechnology company focused on revolutionizing global manufacturing through sustainable and efficient bio-production methods. It specializes in developing cell-free bio-production technology that aims to eliminate the inefficiencies and complexities associated with traditional bio-production. Enzymit employs artificial intelligence and deep learning algorithms to design novel enzymes, which serve as molecular machines capable of transforming abundant feedstocks into valuable products, including pharmaceuticals, cosmetics, food, and materials. The company’s small, modular bio-reactors facilitate this process, promoting resource independence while minimizing environmental impact. By moving away from conventional whole-cell methods to utilizing nature's elemental building blocks, Enzymit enhances cost-effectiveness, efficiency, and sustainability in bio-production, while also providing greater flexibility in product customization for various industries.

Synex Medical is a company focused on advancing health monitoring technology through non-invasive blood testing. It has developed a portable device that utilizes a miniaturized magnetic resonance system to measure blood metabolites without the need for skin penetration. This innovative approach employs only magnets and radio waves, ensuring no adverse health effects for users. By accurately measuring critical metabolites such as glucose, lactate, and ketones, Synex Medical's technology empowers individuals to monitor their health proactively and make informed decisions about their well-being.

Inflammatix is a molecular diagnostics company based in Burlingame, California, founded in 2016. It specializes in developing rapid tests that analyze the immune system to address significant clinical and public health issues. The company's initial focus is on creating tests for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix also builds a diagnostics pipeline based on host response, which includes tests for tropical infections, autoimmune diseases, transplant rejection, and other conditions.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Noetik is an AI-native biotechnology company focused on the discovery and development of cancer immunotherapies. Utilizing advanced machine learning techniques, Noetik's platform identifies new therapeutic targets and designs innovative treatments. By harnessing self-supervised learning and integrating diverse human multimodal data, the company aims to enhance the precision and effectiveness of immunotherapies. This approach enables the development of more personalized cancer treatments, contributing to the advancement of targeted therapies in oncology.

Openwater is a medical technology startup founded in 2016 and based in San Francisco, California. The company specializes in developing advanced wearable devices that utilize novel optoelectronics to achieve MRI-like resolution for medical diagnostics and treatments. By employing LCDs with small pixels, Openwater's technology creates holographic images that reduce scattering, enabling physicians to visualize the inner workings of the body and brain at a cellular level. This innovation allows for precise diagnosis and targeted treatment of diseases by manipulating or destroying individual cells without damaging surrounding tissue. Openwater aims to revolutionize medical imaging and improve patient outcomes through its cutting-edge approach.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Karius, Inc. is a life sciences company based in Redwood City, California, with an additional office in Menlo Park. Founded in 2014, Karius specializes in generating genomic insights for infectious diseases through its innovative Karius Test. This non-invasive blood test utilizes sequencing of microbial cell-free DNA to identify and quantify a wide range of pathogens, including bacteria, DNA viruses, fungi, and parasites. The Karius Test is particularly useful in the diagnosis of complicated pneumonia, infections in immunocompromised patients, and endocarditis, enabling clinicians to make rapid and informed treatment decisions. Karius operates a CLIA-certified and CAP-accredited laboratory, providing high-complexity clinical laboratory testing and offering services for pathogen biomarker detection aimed at biopharmaceutical companies. The company is dedicated to advancing the understanding and management of infectious diseases, striving for a future where these conditions pose less of a threat to human health.

Yoneda Labs is a developer of AI-based software designed to assist chemists in optimizing reaction parameters essential for the synthesis of drugs and materials. The platform enables users to determine critical factors such as temperature, concentration, and catalyst, thereby enhancing the efficiency and speed of chemical laboratory processes. By leveraging advanced artificial intelligence, Yoneda Labs aims to streamline the development of chemical reactions, ultimately facilitating faster innovation in the pharmaceutical and material sciences industries.

Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing innovative therapies that target senescent cells implicated in age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of therapeutic candidates. These candidates are designed to selectively address senescent cells, as well as pro-inflammatory and pro-fibrotic cell populations that contribute to various chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises industry experts with significant experience in drug development and commercialization across both large pharmaceutical companies and biotech firms.

Nabla Bio is a biotechnology company that specializes in the development of an autoreverse platform for the discovery of innovative protein variants. These proteins, which exhibit unique qualities, are engineered to create new medicines and enhance nutritional products. By leveraging insights gained from billions of natural proteins, Nabla Bio enhances these variants through extensive experimentation, allowing for advanced applications in both medical and industrial fields. The company's focus on complex measurements of protein function positions it as a leader in the pursuit of previously unattainable protein capabilities.

Loyal is a biotechnology company focused on developing veterinary pharmaceuticals aimed at extending the health span and lifespan of dogs. The company creates medicines designed to delay the onset of age-related diseases such as cancer, heart disease, and metabolic disorders. By quantifying and regulating the aging process, Loyal seeks to mitigate the effects of aging, thereby promoting healthier and longer lives for dogs. Through its innovative approach, the company aspires to improve the quality of life for pets and enhance their longevity.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Siolta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016 and headquartered in San Francisco, California, the company utilizes its extensive understanding of the developing gut microbiome to promote immune tolerance. Siolta Therapeutics is advancing pharmaceutical-grade anaerobic organisms and is currently in phase 2 of development for its products. By leveraging insights from human microbiome studies, the company aims to create targeted microbial therapeutics and companion diagnostics that facilitate precision medicine in the management of inflammatory diseases.

Moonwalk Biosciences is a genomic medicine startup focused on developing precision epigenetic therapeutics. The company specializes in creating a profiling and engineering technology platform that leverages advanced artificial intelligence predictions to offer a comprehensive view of the epigenome in both health and disease states. This innovative approach aims to revolutionize therapy discovery and development, enabling healthcare providers to reprogram cells back to their healthy state.

Encellin Inc., established in 2016, is a biotechnology company based in San Francisco, California. It specializes in developing innovative thin-film cell encapsulation devices for cell-based therapeutics, aiming to improve the lives of patients with chronic diseases initially focusing on Type 1 diabetes. The company's technology enables encapsulated cells to function as smart molecular factories, providing potential therapeutic solutions.

Eligo Bioscience S.A.S is a biotechnology company founded in 2014 and based in Paris, France, specializing in the development of Eligobiotics, a novel class of antimicrobials. These therapeutics are designed to target specific bacteria based on their genomic information, utilizing a combination of CRISPR/Cas technology and engineered phage capsids. This advanced approach allows Eligo to create precision antibiotics aimed at eradicating resistant pathogens and virulent bacteria within the human microbiome. The applications of Eligobiotics extend beyond pharmaceuticals; they also encompass areas such as cosmetics and biodefense, addressing a variety of bacteria-associated diseases and offering next-generation solutions to combat superbugs.

Vivodyne is a biotechnology company that specializes in developing an advanced automated robotic system aimed at discovering innovative drugs and cellular therapies. The company has created a microfluidic bioengineering platform that focuses on single-cell 4D phenomics, allowing for a detailed exploration of biological complexities. Its technology enables the cultivation of highly realistic human tissue models for drug discovery, incorporating an integrated confocal microscope. This platform not only accelerates the drug development process but also allows researchers to formulate tunable mixtures of compounds and cell therapies. Through its unique approach, Vivodyne seeks to advance the understanding of human health and facilitate the creation of effective treatments for various diseases.

CellFE Inc. is a biotechnology company based in San Carlos, California, established in 2017. It specializes in the development of a microfluidics-based device designed to deliver gene-editing molecules into human cells. This innovative platform enhances the manufacturing and development of cell therapies by utilizing rapid cell compression techniques that facilitate the uptake of therapeutic molecules from surrounding fluids. By enabling the transport of hard-to-deliver molecules, CellFE aims to improve the effectiveness of treatments for various disorders, supporting medical researchers in their efforts to advance patient care and outcomes.

Rejuvenation Technologies Inc., established in 2016 and based in Mountain View, California, is a biotechnology company specializing in developing nucleoside-modified TERT mRNA. This technology safely and rapidly extends telomeres, enabling cells to proliferate more effectively. The company focuses on regenerative medicine applications, aiming to target age-related diseases and conditions across various organs such as the liver, lungs, and immune system. Their offerings include cell therapies like tissue engineering, transplants, skin grafts, immunotherapy, and regeneration medicine.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

SURGE Therapeutics is a biotechnology company focused on enhancing cancer treatment outcomes through innovative immunotherapy solutions. It has developed a proprietary injectable biodegradable hydrogel designed to deliver cancer therapeutics in a prolonged and localized manner. This technology enables targeted release of immunotherapy agents at the surgical site following tumor resection, allowing for more effective treatment administration. By optimizing the timing and location of drug delivery, SURGE Therapeutics aims to improve patient survival rates and minimize systemic side effects, representing a significant advancement in the field of cancer care.

SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

Ceibo is an industrial biotechnology company that specializes in developing innovative technologies for the mining industry. The company has created a proprietary method for leaching copper sulphide and is actively working on solutions to suppress dust generated during mining operations. Ceibo's technology is aimed at enhancing the production of critical minerals essential for the clean energy transition and is designed to optimize the recovery processes from both primary and secondary sulfide ores rich in chalcopyrite. The company is focused on scaling its technology to improve not only copper recovery but also to extend its benefits to other vital minerals. By providing these advanced solutions, Ceibo enables mining clients to enhance operational efficiency, reduce costs, and maintain environmentally sustainable practices with minimal waste.

Tachyon Therapeutics is a biotechnology company focused on research and development aimed at creating innovative therapeutics for cancer treatment. The company is dedicated to developing first-in-class compounds that target new drug mechanisms in cancer biology, employing advanced techniques in molecular cancer biology, epigenetics, and cancer stem cell research. Currently, Tachyon is conducting Phase 1 clinical trials to evaluate the safety, pharmacokinetics, and anti-tumor effectiveness of its lead candidate, TACH101, in patients with advanced cancer. Through a commitment to high-quality and scientifically sound practices, Tachyon aims to provide novel treatment options that unlock new pathways for addressing complex cancer cases.

IgGenix, Inc. is a biotechnology company focused on developing an innovative antibody therapeutics platform aimed at treating food and non-food allergies, as well as other severe allergic conditions. The company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies, which are designed to alleviate and potentially prevent allergic reactions. By capturing and analyzing rare human B cells that express allergen-binding antibodies, IgGenix engineers these antibodies to incorporate immune-modulating activities derived from the IgG class, thereby enhancing their ability to suppress allergic responses. Founded in 2019 and based in South San Francisco, California, IgGenix is dedicated to addressing the challenges posed by life-threatening allergic reactions through its advanced therapeutic solutions.

Synchron is a medical technology company focused on developing innovative brain-computer interface solutions. It manufactures an implantable device known as the stentrode, which is delivered to the brain via a catheter. This minimally invasive device is embedded with electrode arrays that can interpret neuronal signals and modulate neural activity in targeted areas. By enabling patients with motor impairments to control digital devices, prosthetics, and other assistive technologies through thought, Synchron aims to enhance the quality of life for individuals with disabilities.

Bionaut Labs, established in 2016 and based in Palo Alto, California, specializes in the design, manufacture, and control of intra-tissue navigation platforms. The company's core technology involves nano/micro robots, dubbed 'Bionauts', which operate within the body to deliver treatments with anatomical precision. Bionaut Labs aims to revolutionize the treatment of central nervous system disorders by enabling new therapeutic technologies like gene therapy and CRISPR-Cas9 in challenging clinical settings. Their remote-controlled micro-robots allow for precise targeting, tracking, and payload release, potentially automating complex surgeries remotely without external incisions.

SURGE Therapeutics is a biotechnology company focused on enhancing cancer treatment outcomes through innovative immunotherapy solutions. It has developed a proprietary injectable biodegradable hydrogel designed to deliver cancer therapeutics in a prolonged and localized manner. This technology enables targeted release of immunotherapy agents at the surgical site following tumor resection, allowing for more effective treatment administration. By optimizing the timing and location of drug delivery, SURGE Therapeutics aims to improve patient survival rates and minimize systemic side effects, representing a significant advancement in the field of cancer care.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines specifically for transplanted livers and the treatment of fatty liver conditions. Founded in 2019 and based in Headington, United Kingdom, the company employs advanced genomic techniques to identify and inhibit overactive genes associated with liver diseases. This approach includes testing therapies in discarded donor livers that are maintained outside the body, ensuring that potential treatments can be evaluated in a relevant biological context. With over 15 years of expertise in liver genomics research, Ochre Bio aims to create a pipeline of innovative medicines that address liver and liver-mediated conditions, ultimately enhancing the availability of healthy livers for transplantation and reducing complications associated with cirrhosis. The company operates within Oxford's biotechnology innovation hub, leveraging its scientific foundation to advance therapeutic solutions in the field of liver health.

Equii is a food technology company founded in 2021 by Monica Bhatia, located in San Ramon, California. The company specializes in discovering and utilizing highly nutritious sources of microbial proteins to ferment grains, resulting in high-protein grain flours. Equii's innovative technology transforms agricultural crops into nutritionally balanced products, aimed at providing healthy food options for various eating occasions. By focusing on complete protein sources, Equii enhances the nutritional value of its offerings, making them accessible to consumers seeking healthier dietary choices.

Carver Biosciences is a biotechnology company specializing in the development of CRISPR/Cas13-based antiviral therapies. The company's innovative approach focuses on utilizing the Cas13 technology to target and destroy RNA viruses at the molecular level, particularly respiratory viruses. By eliminating these viruses, Carver aims to prevent their replication, thereby providing a therapeutic option that complements existing vaccinations and antiviral treatments. This technology is designed to help patients manage infections more effectively, potentially arresting disease progression and offering alternative treatment solutions in the face of viral challenges.

Arpeggio Bio, established in 2017 and headquartered in Boulder, Colorado, specializes in developing innovative software that captures snapshots of cellular RNA activity. By combining biological assays with advanced machine learning algorithms, the company enables pharmaceutical and biotechnology firms to understand a drug's mechanism of action at low sequencing depths. Arpeggio Bio's technology reveals intricate biological networks, facilitating more informed therapeutic development.

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

Genecis is an early-stage organic waste processing startup that uses biotechnology to convert waste into biodegradable plastics and other high-value materials. It converts organic waste into PHA (Polyhydroxyalkanoate), a biodegradable, compostable, and non-toxic polymer that can be tuned to replace a wide variety of traditional plastics. PHA can be used for single-use plastics, clothing and textiles, automotive interiors, medical tools and products, and food contact applications.

Faeth Therapeutics is a healthcare company dedicated to enhancing cancer treatment through a deep understanding of the relationship between dietary nutrients and tumor growth. By aligning specific diets with tumor genotypes and treatment regimens, Faeth aims to limit the energy and resources that tumors need to proliferate, thereby improving patient outcomes in cancer therapy. Founded by leading researchers and clinicians, the company seeks to translate significant discoveries from cancer research laboratories into effective clinical practices, focusing on evidence-based approaches to optimize treatment strategies for cancer patients.

CHARM Therapeutics is a biotechnology company focused on delivering innovative medicines by leveraging advanced 3D deep learning and drug discovery technologies. Its platform is designed to address challenging disease targets that are typically considered undruggable, thereby enhancing treatment options for patients. By utilizing cutting-edge methodologies, CHARM Therapeutics aims to develop therapeutics with transformational efficacy, ultimately assisting healthcare professionals in improving patient outcomes.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Anagenex is a seed stage biotechnology company that specializes in drug discovery, focusing on challenging medical targets. The company has developed an innovative platform that significantly accelerates the discovery of small molecule drugs and the identification of pharmaceutical compounds. By utilizing machine learning in conjunction with DNA-encoded libraries, Anagenex's technology can rapidly analyze a vast number of compounds, generating extensive data sets and conducting parallel biochemical experiments. This capability is enhanced by proprietary artificial intelligence models, which facilitate the development of new therapeutic drugs aimed at addressing critical medical needs.

Ultima Genomics is a biotechnology company established in 2016 and headquartered in Newark, California. It specializes in genome-scale sequencing technology, focusing on providing analytical services to various enterprises. By employing an open substrate, Ultima Genomics creates a vast, low-cost reaction surface that facilitates billions of reads without relying on expensive flow cells or complex fluidic systems. The company utilizes specialized sequencing hardware combined with machine learning techniques to ensure reproducible and accurate results. This innovative approach enables clients to obtain genomic reports at scale, enhancing the speed and efficiency of sequencing while significantly reducing costs. Ultima Genomics aims to harness the potential of genomic information to drive advancements in biology and improve human health.

Oobli is a food company focused on developing innovative protein sweeteners derived from exotic plants. These unique sweeteners offer a delicious taste while significantly reducing calories, making them a healthier alternative to traditional sugars. Produced through fermentation, Oobli's sweeteners have no glycemic impact and do not influence the gut microbiome, allowing consumers to enjoy sweetness without concerns related to blood sugar, insulin, or weight management. The company has successfully obtained regulatory approvals, including FDA "no questions" letters and GRAS status for multiple protein sources, which positions it as a leader in the healthy sweetener market. By transforming flavors, Oobli aims to enhance everyday food experiences while promoting better health outcomes for its users.

Mirvie is a biotechnology company specializing in non-invasive tests for maternal-fetal health, aimed at enhancing the safety of pregnancy. Founded in 2018 by Maneesh Jain and based in South San Francisco, California, Mirvie provides predictive diagnostic tools that deliver actionable insights to expectant mothers and families. Its medical diagnostic platform enables healthcare practitioners to identify at-risk pregnancies, facilitating timely interventions and therapeutic approaches to improve pregnancy outcomes. Through its innovative solutions, Mirvie seeks to empower families with critical information, ensuring a safer pregnancy experience.

VitroLabs, Inc. is a San Jose, California-based startup specializing in 3D tissue engineering and biomaterials. Founded in 2016, the company focuses on developing innovative, scalable solutions for creating authentic leather and other luxury materials through advanced stem cell technologies. By leveraging breakthroughs in tissue engineering, VitroLabs produces lab-grown leather that eliminates the need for animal raising and slaughter, promoting sustainability in the fashion and interior design industries. Its unique approach allows fashion brands to manufacture high-quality products while adhering to ethical practices.

Turn.bio is a biotechnology company focused on developing innovative therapies aimed at reversing aging and age-related diseases. Leveraging a patented mRNA platform technology known as ERA, along with a specialized delivery system called eTurna, the company targets the epigenome to restore optimal gene expression. By designing tailored therapies, Turn.bio addresses a range of conditions, including immune-related diseases such as cancer, dermatological issues, and ailments in ophthalmology, osteoarthritis, and the muscular system. The company's approach involves inducing the body to heal itself by instructing specific cells to combat disease and repair damaged tissue, thereby reprogramming cellular functions to enhance health and longevity.

Volta Labs, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. The company specializes in engineering and developing innovative tools for biological automation, focusing on scalable automation solutions for genetic engineering. Its platform is designed to revolutionize genomics research by providing affordable genomic sample preparation and automation for complex biological workflows. By integrating expertise from engineering, surface chemistry, and molecular biology, Volta Labs aims to streamline sample processing and enhance the capabilities of biotech organizations in the next generation of genomic automation.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Cellino is focused on developing a scalable, automated biomanufacturing system aimed at producing personalized cell therapies. The company's innovative platform leverages AI-guided laser editing to generate autologous induced pluripotent stem cells (iPSCs) efficiently and at scale. By utilizing image-guided machine learning, single-cell laser processing, and robotics, Cellino seeks to make advanced, potentially curative treatments accessible for a range of chronic degenerative diseases, including vision loss and Parkinson's disease. The company's mission is to transform healthcare by enabling personalized therapies that can significantly improve patient outcomes and overall health.

Faeth Therapeutics is a healthcare company dedicated to enhancing cancer treatment through a deep understanding of the relationship between dietary nutrients and tumor growth. By aligning specific diets with tumor genotypes and treatment regimens, Faeth aims to limit the energy and resources that tumors need to proliferate, thereby improving patient outcomes in cancer therapy. Founded by leading researchers and clinicians, the company seeks to translate significant discoveries from cancer research laboratories into effective clinical practices, focusing on evidence-based approaches to optimize treatment strategies for cancer patients.

Anagenex is a seed stage biotechnology company that specializes in drug discovery, focusing on challenging medical targets. The company has developed an innovative platform that significantly accelerates the discovery of small molecule drugs and the identification of pharmaceutical compounds. By utilizing machine learning in conjunction with DNA-encoded libraries, Anagenex's technology can rapidly analyze a vast number of compounds, generating extensive data sets and conducting parallel biochemical experiments. This capability is enhanced by proprietary artificial intelligence models, which facilitate the development of new therapeutic drugs aimed at addressing critical medical needs.

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

NextVivo is a biotech company focused on advancing drug development through its innovative immune organoid technology platform. The company aims to create safer and more effective therapies by utilizing immune-competent, human-derived models. Its technology involves the use of miniature 3D cell cultures, known as organoids, which accurately replicate the composition, structure, and function of human tissue. This unique approach allows for the modeling of both humoral and cellular immune responses outside the human body. By enabling the testing of pre-clinical candidates on ex vivo human tissue models, NextVivo facilitates the identification of the most promising therapies for clinical development, thereby enhancing the drug discovery process.

Nabla Bio is a biotechnology company that specializes in the development of an autoreverse platform for the discovery of innovative protein variants. These proteins, which exhibit unique qualities, are engineered to create new medicines and enhance nutritional products. By leveraging insights gained from billions of natural proteins, Nabla Bio enhances these variants through extensive experimentation, allowing for advanced applications in both medical and industrial fields. The company's focus on complex measurements of protein function positions it as a leader in the pursuit of previously unattainable protein capabilities.

Fountain Therapeutics, established in 2018 and headquartered in San Francisco, specializes in developing treatments for age-related diseases using cellular models and an AI-based platform for target discovery. The company aims to recreate aging's complex hallmarks in lab dishes, combining this model with artificial intelligence and computer vision to identify novel targets unbiasedly.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

Vertical Oceans is a company that specializes in the sustainable production of same-day farm-to-fork shrimp through its innovative vertical aqua towers located in urban markets. The company employs a unique system that integrates 83 advanced technologies across bioengineering, hardware engineering, and computational engineering. Central to this system is the Intelligent Habitat (iHAB), a self-sustaining and self-cleaning modular production unit that fosters a distinctive aquatic ecosystem. This ecosystem incorporates fish and seaweed for biofiltration, creating a more natural environment that enhances the quality and taste of the shrimp. Vertical Oceans emphasizes sustainability by operating without chemicals or antibiotics and generating no effluent, ensuring that its production methods align with environmentally responsible practices.

Supplant is a biotechnology platform working in the food sector. It develops natural food ingredients from agricultural resources to allow food manufacturers to decrease sugar, increase fiber, and boost the gut health-promoting qualities of its products.

Pearl Bio is a synthetic biology company focused on innovating biologics and biomaterials through advanced technologies. It has developed a platform that encompasses genome engineering, ribosome engineering, and biomanufacturing. This platform enables the creation of smart biologics and biomaterials, allowing scientists to enhance their understanding of gene function. By employing these techniques, Pearl Bio aims to facilitate the development of products, tools, and processes that can be scaled for commercial use, ultimately contributing to the treatment of genetic and acquired diseases.

VitroLabs, Inc. is a San Jose, California-based startup specializing in 3D tissue engineering and biomaterials. Founded in 2016, the company focuses on developing innovative, scalable solutions for creating authentic leather and other luxury materials through advanced stem cell technologies. By leveraging breakthroughs in tissue engineering, VitroLabs produces lab-grown leather that eliminates the need for animal raising and slaughter, promoting sustainability in the fashion and interior design industries. Its unique approach allows fashion brands to manufacture high-quality products while adhering to ethical practices.

Loyal is a biotechnology company focused on developing veterinary pharmaceuticals aimed at extending the health span and lifespan of dogs. The company creates medicines designed to delay the onset of age-related diseases such as cancer, heart disease, and metabolic disorders. By quantifying and regulating the aging process, Loyal seeks to mitigate the effects of aging, thereby promoting healthier and longer lives for dogs. Through its innovative approach, the company aspires to improve the quality of life for pets and enhance their longevity.

Karma Biotechnologies, Inc. is a biotechnology company based in Los Angeles, California, focused on developing innovative therapies for autoimmune diseases, allergies, and food sensitivities. Established in 2019, the company has introduced Xavines, a precision immunotherapy platform aimed at addressing the critical need for antigen-specific treatments that target only the harmful immune cells responsible for these conditions. Unlike conventional approaches that rely on general immune suppression, Karma's technology is designed to promote antigen-specific immune tolerance in vivo. By leveraging expertise in immunology and lipid nanoparticle engineering, the company aims to create off-the-shelf therapeutics that effectively switch off the rogue immune responses associated with autoimmunity and related disorders, thereby enhancing the treatment landscape for these conditions.

Known Medicine Inc. is a biotechnology company based in Salt Lake City, Utah, founded in 2020. The company specializes in developing a custom organoid platform designed for tumor sensitivity testing through advanced bioengineering techniques. Known Medicine focuses on transforming the process of evaluating how tumors respond to cancer therapies by taking tumor samples and breaking them down into microtumors. These microtumors are treated in specialized micro-environments using various methods to ascertain the most effective treatment options. The company's platform integrates machine learning with omics data to identify predictive biomarkers that inform oncologists about cancer cell behavior and potential treatment pathways, ultimately aiming to enhance personalized cancer care.

Encellin Inc., established in 2016, is a biotechnology company based in San Francisco, California. It specializes in developing innovative thin-film cell encapsulation devices for cell-based therapeutics, aiming to improve the lives of patients with chronic diseases initially focusing on Type 1 diabetes. The company's technology enables encapsulated cells to function as smart molecular factories, providing potential therapeutic solutions.

Deep Genomics Inc. is an artificial intelligence therapeutics company based in Toronto, Canada, founded in 2014. The company focuses on developing individualized genetic medicines by utilizing AI systems to enhance various aspects of drug discovery and development, such as target discovery, lead optimization, toxicity assessment, and innovative trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic underpinnings of diseases at the RNA and DNA levels, targeting rare metabolic, ophthalmologic, and neurodegenerative disorders. Its AI-powered platform decodes the complexities of RNA biology, enabling the identification of novel therapeutic targets and mechanisms that traditional methods cannot access. This innovative approach positions Deep Genomics at the forefront of revolutionizing drug discovery, ultimately aiming to provide new treatments for currently untreatable diseases.

IgGenix, Inc. is a biotechnology company focused on developing an innovative antibody therapeutics platform aimed at treating food and non-food allergies, as well as other severe allergic conditions. The company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies, which are designed to alleviate and potentially prevent allergic reactions. By capturing and analyzing rare human B cells that express allergen-binding antibodies, IgGenix engineers these antibodies to incorporate immune-modulating activities derived from the IgG class, thereby enhancing their ability to suppress allergic responses. Founded in 2019 and based in South San Francisco, California, IgGenix is dedicated to addressing the challenges posed by life-threatening allergic reactions through its advanced therapeutic solutions.

Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines specifically for transplanted livers and the treatment of fatty liver conditions. Founded in 2019 and based in Headington, United Kingdom, the company employs advanced genomic techniques to identify and inhibit overactive genes associated with liver diseases. This approach includes testing therapies in discarded donor livers that are maintained outside the body, ensuring that potential treatments can be evaluated in a relevant biological context. With over 15 years of expertise in liver genomics research, Ochre Bio aims to create a pipeline of innovative medicines that address liver and liver-mediated conditions, ultimately enhancing the availability of healthy livers for transplantation and reducing complications associated with cirrhosis. The company operates within Oxford's biotechnology innovation hub, leveraging its scientific foundation to advance therapeutic solutions in the field of liver health.

Synchron is a medical technology company focused on developing innovative brain-computer interface solutions. It manufactures an implantable device known as the stentrode, which is delivered to the brain via a catheter. This minimally invasive device is embedded with electrode arrays that can interpret neuronal signals and modulate neural activity in targeted areas. By enabling patients with motor impairments to control digital devices, prosthetics, and other assistive technologies through thought, Synchron aims to enhance the quality of life for individuals with disabilities.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive food analytics platform that utilizes next-generation sequencing and data analytics to enhance food safety and quality control. Its offerings include Clear Dx™ and Clear Safety™, which facilitate the rapid identification of pathogens and support public health initiatives. Clear Labs' platform delivers critical insights into the molecular composition of foods and ingredients, testing for authenticity, contaminants, allergens, and other safety parameters. By offering transparency across supply chains, the company serves food manufacturers, suppliers, and retailers, enabling them to improve operational efficiency and safety through detailed analytics and reporting.

Overture Life, Inc. is a biotechnology company based in New York, established in 2017, that specializes in developing robotic solutions for in vitro fertilization (IVF) applications. The company focuses on automating the IVF process through innovative medical devices and embryo testing methodologies, which enhance the efficiency and success rates of fertility treatments. By optimizing resource use and lowering costs, Overture Life aims to make IVF more accessible to a broader audience. Its technology includes automated cryopreservation and embryo testing services, enabling fertility clinics to identify viable embryos prior to implantation, thereby improving patient outcomes and supporting individuals in their journey to parenthood.

Apton Biosystems, Inc. is a biotechnology company based in Pleasanton, California, founded in 2012. The company specializes in developing advanced optical systems for sequencing and protein detection, utilizing super-resolution technology to analyze molecules that are spaced closer than the wavelength of light. This innovative approach facilitates multi-omic sequencing and single-molecule protein detection, significantly enhancing capabilities in biomarker discovery, early disease detection, and therapeutic monitoring. Apton Biosystems aims to advance preventive health and precision medicine by addressing spatial challenges in high-density sequencing and protein analysis, thus contributing to improved healthcare outcomes.

Turn.bio is a biotechnology company focused on developing innovative therapies aimed at reversing aging and age-related diseases. Leveraging a patented mRNA platform technology known as ERA, along with a specialized delivery system called eTurna, the company targets the epigenome to restore optimal gene expression. By designing tailored therapies, Turn.bio addresses a range of conditions, including immune-related diseases such as cancer, dermatological issues, and ailments in ophthalmology, osteoarthritis, and the muscular system. The company's approach involves inducing the body to heal itself by instructing specific cells to combat disease and repair damaged tissue, thereby reprogramming cellular functions to enhance health and longevity.

Pendulum Therapeutics Inc., established in 2013 and headquartered in San Francisco, specializes in developing microbiome-targeted therapies for managing chronic illnesses, with a focus on type 2 diabetes. The company's flagship product, Pendulum Glucose Control, is a medical probiotic clinically proven to lower blood sugar spikes and reduce A1C levels. Pendulum Therapeutics uses evidence-based microbiome science and DNA sequencing, backed by a portfolio of patents and pending applications, to create targeted probiotics and prebiotics. The company sells its products online and has raised over $111 million in funding from prominent investors.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.

Inflammatix is a molecular diagnostics company based in Burlingame, California, founded in 2016. It specializes in developing rapid tests that analyze the immune system to address significant clinical and public health issues. The company's initial focus is on creating tests for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix also builds a diagnostics pipeline based on host response, which includes tests for tropical infections, autoimmune diseases, transplant rejection, and other conditions.

Bionaut Labs, established in 2016 and based in Palo Alto, California, specializes in the design, manufacture, and control of intra-tissue navigation platforms. The company's core technology involves nano/micro robots, dubbed 'Bionauts', which operate within the body to deliver treatments with anatomical precision. Bionaut Labs aims to revolutionize the treatment of central nervous system disorders by enabling new therapeutic technologies like gene therapy and CRISPR-Cas9 in challenging clinical settings. Their remote-controlled micro-robots allow for precise targeting, tracking, and payload release, potentially automating complex surgeries remotely without external incisions.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Supplant is a biotechnology platform working in the food sector. It develops natural food ingredients from agricultural resources to allow food manufacturers to decrease sugar, increase fiber, and boost the gut health-promoting qualities of its products.

Cellino is focused on developing a scalable, automated biomanufacturing system aimed at producing personalized cell therapies. The company's innovative platform leverages AI-guided laser editing to generate autologous induced pluripotent stem cells (iPSCs) efficiently and at scale. By utilizing image-guided machine learning, single-cell laser processing, and robotics, Cellino seeks to make advanced, potentially curative treatments accessible for a range of chronic degenerative diseases, including vision loss and Parkinson's disease. The company's mission is to transform healthcare by enabling personalized therapies that can significantly improve patient outcomes and overall health.

Ukko is a biotechnology company focused on enhancing the quality of life for individuals affected by food allergies and disorders. The company utilizes a computational engineering platform that employs artificial intelligence, immunology, and protein engineering to redesign food allergens into therapeutics that are both safe and effective. By creating a comprehensive, clinically validated map of the molecular structures associated with food allergies, Ukko reveals critical insights into the biological mechanisms governing human-food interactions. This innovative approach enables the development of new protein versions that do not provoke an immune response, providing a novel strategy for treating protein-based allergies.

Earli is a biotechnology company focused on advancing cancer detection and treatment through innovative technology. The company specializes in developing devices that utilize a novel gene therapy approach known as Synthetic Biopsy. This method compels cancer cells to produce synthetic biomarkers, which are not naturally occurring in the human body. These biomarkers can then be detected in bodily fluids such as blood, urine, or breath, allowing for early identification of cancer. By facilitating the early detection of homogeneous tumors, Earli aims to significantly improve the chances of successful treatment and personalize therapy options for patients. Additionally, the technology is designed to be visible during imaging procedures such as PET scans, enhancing the monitoring of cancer progression and treatment efficacy.

Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing innovative therapies that target senescent cells implicated in age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of therapeutic candidates. These candidates are designed to selectively address senescent cells, as well as pro-inflammatory and pro-fibrotic cell populations that contribute to various chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises industry experts with significant experience in drug development and commercialization across both large pharmaceutical companies and biotech firms.

Advanced Chemotherapy Technologies is a healthcare company that is developing breakthrough combination drug-device technologies for treating pancreatic cancer.

Siolta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016 and headquartered in San Francisco, California, the company utilizes its extensive understanding of the developing gut microbiome to promote immune tolerance. Siolta Therapeutics is advancing pharmaceutical-grade anaerobic organisms and is currently in phase 2 of development for its products. By leveraging insights from human microbiome studies, the company aims to create targeted microbial therapeutics and companion diagnostics that facilitate precision medicine in the management of inflammatory diseases.

Invoy is a company focused on enhancing health and weight loss outcomes through the integration of science, data, and artificial intelligence. It develops a monitoring medical device that offers personalized nutrition and wellness services by generating real-time data on an individual's metabolism. This device not only provides tailored, predictive nutrition recommendations but also features affordable breath analyzers for medical applications. By addressing the unique body chemistry of each individual, Invoy aims to empower users to achieve their specific health and wellness objectives.

SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

IgGenix, Inc. is a biotechnology company focused on developing an innovative antibody therapeutics platform aimed at treating food and non-food allergies, as well as other severe allergic conditions. The company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies, which are designed to alleviate and potentially prevent allergic reactions. By capturing and analyzing rare human B cells that express allergen-binding antibodies, IgGenix engineers these antibodies to incorporate immune-modulating activities derived from the IgG class, thereby enhancing their ability to suppress allergic responses. Founded in 2019 and based in South San Francisco, California, IgGenix is dedicated to addressing the challenges posed by life-threatening allergic reactions through its advanced therapeutic solutions.

Oobli is a food company focused on developing innovative protein sweeteners derived from exotic plants. These unique sweeteners offer a delicious taste while significantly reducing calories, making them a healthier alternative to traditional sugars. Produced through fermentation, Oobli's sweeteners have no glycemic impact and do not influence the gut microbiome, allowing consumers to enjoy sweetness without concerns related to blood sugar, insulin, or weight management. The company has successfully obtained regulatory approvals, including FDA "no questions" letters and GRAS status for multiple protein sources, which positions it as a leader in the healthy sweetener market. By transforming flavors, Oobli aims to enhance everyday food experiences while promoting better health outcomes for its users.

Menten AI, established in 2018 with headquarters in San Francisco and a satellite office in Toronto, is an early-stage biotech company specializing in drug discovery. It leverages machine learning and quantum computing to develop novel protein-based drugs and enzymes for pharmaceutical and chemical industries. Menten AI's core offering is a proprietary protein design algorithm tailored for current and near-term quantum computers, enabling efficient exploration of protein structures for therapeutic applications, such as oncology and neurodegeneration, and industrial enzyme development.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive food analytics platform that utilizes next-generation sequencing and data analytics to enhance food safety and quality control. Its offerings include Clear Dx™ and Clear Safety™, which facilitate the rapid identification of pathogens and support public health initiatives. Clear Labs' platform delivers critical insights into the molecular composition of foods and ingredients, testing for authenticity, contaminants, allergens, and other safety parameters. By offering transparency across supply chains, the company serves food manufacturers, suppliers, and retailers, enabling them to improve operational efficiency and safety through detailed analytics and reporting.

Genalyte, Inc. is a clinical and diagnostic life sciences company based in San Diego, California, that specializes in rapid diagnostic testing solutions for healthcare providers, patients, and researchers. Founded in 2007, Genalyte has developed a unique technology platform employing silicon photonic biosensors to quantify the interactions between biomolecules, such as antibodies and proteins. This innovative approach allows for the direct measurement of protein binding and nucleic acid hybridization, facilitating the monitoring of autoimmune diseases, cancer biomarker screening, and the detection of infectious agents, including Ebola. The company's Maverick platform enables rapid testing in various healthcare settings, with results typically available in under thirty minutes, thereby enhancing patient care and improving resource efficiency within the healthcare system.

E25Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018, that focuses on developing rapid diagnostic tests for epidemic fever viruses. The company designs paper-based diagnostic systems and kits that facilitate the detection of viruses such as dengue, chikungunya, and Zika. E25Bio's innovative platform enables multiplexed testing that quickly identifies viral antigens during infections, allowing for real-time data reporting through a mobile application. This capability supports epidemiologic predictions and disease mapping, empowering governments and health organizations to respond effectively to outbreaks and manage public health crises. Through its commitment to fast, mobile testing solutions, E25Bio aims to prevent severe health outcomes associated with viral epidemics.

Karius, Inc. is a life sciences company based in Redwood City, California, with an additional office in Menlo Park. Founded in 2014, Karius specializes in generating genomic insights for infectious diseases through its innovative Karius Test. This non-invasive blood test utilizes sequencing of microbial cell-free DNA to identify and quantify a wide range of pathogens, including bacteria, DNA viruses, fungi, and parasites. The Karius Test is particularly useful in the diagnosis of complicated pneumonia, infections in immunocompromised patients, and endocarditis, enabling clinicians to make rapid and informed treatment decisions. Karius operates a CLIA-certified and CAP-accredited laboratory, providing high-complexity clinical laboratory testing and offering services for pathogen biomarker detection aimed at biopharmaceutical companies. The company is dedicated to advancing the understanding and management of infectious diseases, striving for a future where these conditions pose less of a threat to human health.